Investigational drug · Phase 2
BI-1808
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BI-1808"
First trial start
2021
Jan 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI-1808", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignancies
- Ovarian Cancer
- T-cell Lymphoma
- Melanoma
Approved drugs for the same conditions: Melanoma · Ovarian cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BI-1808" as an intervention, largest first.
BioInvent International ABIndustry
NCT04752826 · 250 participants (planned) · Start Jan 25, 2021 · Primary completion Jan 31, 2028
Drug: BI-1808; Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection and 1 more · For: Advanced Malignancies; Ovarian Cancer; T-cell Lymphoma and 1 more
Sites: Duarte, California; New York, New York; Philadelphia, Pennsylvania · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.
Teige I, Rohrberg KS, Carneiro A, et al. · Clin Cancer Res 2026
- Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.
Mårtensson L, Holmkvist P, Cleary KL, et al. · Cancer Res 2026
Also in development for Advanced Malignancies
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- BGB-15025Phase 33 trials
BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- CMP 001VidutolimodPhase 32 trials
Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.